-transparent.png){kind=logo}
Resistant variants were selected in vitro against two novel nucleoside analogues, (+) dOTC and (-) dOTFC using the HIV-1 molecular clone HXB2D. The variants obtained displayed 6.5-fold and 10-fold resistance to these compounds, respectively. Cloning and sequencing of the RT genes of the selected viruses identified two mutations, M184I for (+) dOTC and M184V for (-) dOTFC. Results with mutated recombinant clones of HXB2D confirmed the importance of these mutations in MT-4 cells. The resistance profiles of clinical samples with wild-type or 3TC-resistant phenotypes were also studied; low to moderate levels of cross-resistance were observed against the novel compounds.
Related Publications
N Richard, and
H Salomon, and
M Oliveira, and
R Rando, and
M A Wainberg
July 2000,
Antiviral chemistry & chemotherapy,
N Richard, and
H Salomon, and
M Oliveira, and
R Rando, and
M A Wainberg
August 1999,
Antimicrobial agents and chemotherapy,
N Richard, and
H Salomon, and
M Oliveira, and
R Rando, and
M A Wainberg
January 1999,
Antiviral therapy,
N Richard, and
H Salomon, and
M Oliveira, and
R Rando, and
M A Wainberg
June 2000,
Antimicrobial agents and chemotherapy,
N Richard, and
H Salomon, and
M Oliveira, and
R Rando, and
M A Wainberg
October 1967,
Chemical & pharmaceutical bulletin,
N Richard, and
H Salomon, and
M Oliveira, and
R Rando, and
M A Wainberg
April 1967,
Chemical & pharmaceutical bulletin,
N Richard, and
H Salomon, and
M Oliveira, and
R Rando, and
M A Wainberg
January 1995,
Journal of medicinal chemistry,
N Richard, and
H Salomon, and
M Oliveira, and
R Rando, and
M A Wainberg
January 1999,
Nucleosides & nucleotides,
N Richard, and
H Salomon, and
M Oliveira, and
R Rando, and
M A Wainberg
December 2000,
Acta crystallographica. Section C, Crystal structure communications,
N Richard, and
H Salomon, and
M Oliveira, and
R Rando, and
M A Wainberg
March 2000,
Antimicrobial agents and chemotherapy,
